The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade

The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design. The extent of cross-clade conservation of HIV oligomannose glycans is therefore a critical consideration for the development of HIV prophylaxes. We measured the oligomannose content of virion-associated gp120 from primary virus from PBMCs for a range of viral isolates and showed cross-clade elevation (62-79%) of these glycans relative to recombinant, monomeric gp120 (～30%). We also confirmed that pseudoviral production systems can give rise to notably elevated gp120 oligomannose levels (～98%), compared to gp120 derived from a single-plasmid viral system using the HIV(LAI) backbone (56%). This study highlights differences in glycosylation between virion-associated and recombinant gp120.     

Quantitative trait locus (QTL) isogenic recombinant analysis: a method for high-resolution mapping of QTL within a single population

In the quest for fine mapping quantitative trait loci (QTL) at a subcentimorgan scale, several methods that involve the construction of inbred lines and the generation of large progenies of such inbred lines have been developed (Complex Trait Consortium 2003). Here we present an alternative method that significantly speeds up QTL fine mapping by using one segregating population. As a first step, a rough mapping analysis is performed on a small part of the population. Once the QTL have been mapped to a chromosomal interval by standard procedures, a large population of 1000 plants or more is analyzed with markers flanking the defined QTL to select QTL isogenic recombinants (QIRs). QIRs bear a recombination event in the QTL interval of interest, while other QTL have the same homozygous genotype. Only these QIRs are subsequently phenotyped to fine map the QTL. By focusing at an early stage on the informative individuals in the population only, the efforts in population genotyping and phenotyping are significantly reduced as compared to prior methods. The principles of this approach are demonstrated by fine mapping an erucic acid QTL of rapeseed at a subcentimorgan scale.     

Extended Bayesian LASSO for Multiple Quantitative Trait Loci Mapping and Unobserved Phenotype Prediction

The Bayesian LASSO (BL) has been pointed out to be an effective approach to sparse model representation and successfully applied to quantitative trait loci (QTL) mapping and genomic breeding value (GBV) estimation using genome-wide dense sets of markers. However, the BL relies on a single parameter known as the regularization parameter to simultaneously control the overall model sparsity and the shrinkage of individual covariate effects. This may be idealistic when dealing with a large number of predictors whose effect sizes may differ by orders of magnitude. Here we propose the extended Bayesian LASSO (EBL) for QTL mapping and unobserved phenotype prediction, which introduces an additional level to the hierarchical specification of the BL to explicitly separate out these two model features. Compared to the adaptiveness of the BL, the EBL is “doubly adaptive” and thus, more robust to tuning. In simulations, the EBL outperformed the BL in regard to the accuracy of both effect size estimates and phenotypic value predictions, with comparable computational time. Moreover, the EBL proved to be less sensitive to tuning than the related Bayesian adaptive LASSO (BAL), which introduces locus-specific regularization parameters as well, but involves no mechanism for distinguishing between model sparsity and parameter shrinkage. Consequently, the EBL seems to point to a new direction for QTL mapping, phenotype prediction, and GBV estimation.REGULARIZATION or shrinkage methods are gaining increasing recognition as a valuable alternative to variable selection techniques in dealing with oversaturated or otherwise ill-defined regression problems in both the classical and Bayesian frameworks (e.g., O''hara and Sillanpää 2009). Many studies (e.g., Xu 2003; Wang et al. 2005; Zhang and Xu 2005; De los Campos et al. 2009; Usai et al. 2009; Wu et al. 2009; Xu et al. 2009) have documented the potential of shrinkage methods for quantitative trait locus (QTL) mapping and genomic breeding value (GBV) estimation using genome-wide dense sets of markers. Lee et al. (2008) make a clear connection between phenotype prediction and GBV estimation, suggesting that methods developed for one are also applicable to the other. We thus use the two concepts interchangeably throughout this article.Regularized regression methods, such as ridge regression (Hoerl and Kennard 1970) or the least absolute shrinkage and selection operator (LASSO) (Tibshirani 1996), are essentially penalized likelihood procedures, where suitable penalty functions are added to the negative log-likelihood to automatically shrink spurious effects (effects of redundant covariates) toward zero, while allowing relevant effects to take values farther from zero.It has been pointed out that these non-Bayesian shrinkage methods are not suitable for oversaturated models. Zou and Hastie (2005) and Park and Casella (2008) noted that the LASSO cannot select a number of nonzero effects exceeding the sample size. Xu (2003) found that for ridge regression to work, the number of model effects should be in the same order as the number of observations. This is impractical for genomic selection, which capitalizes on the variation due to small-marker effects, the number of which can exceed the sample size, by contrast to QTL mapping where interest lies mostly in a small subset of loci with large effects on the focal phenotype. In connection with the LASSO, the Bayesian LASSO (BL) (Park and Casella 2008; Yi and Xu 2008) has been proposed to overcome this limitation by imposing a selective shrinkage across regression parameters. Xu (2003) also proposed a Bayesian shrinkage method for QTL mapping, which extends ridge regression in a similar fashion.Although the BL has been successfully applied to QTL mapping (e.g., Yi and Xu 2008) and to GBV estimation (e.g., De los Campos et al. 2009), it relies on a single parameter known as the regularization parameter to simultaneously regulate the overall model sparsity and the extent to which individual regression coefficients are shrunken. However, this is unrealistic when dealing with a large number of predictors whose effect sizes may differ by orders of magnitude. It is therefore natural to ask whether this practice can be relaxed and how such an attempt may impinge on the model performance (e.g., Sun et al. 2010).Here we propose an extension to the Bayesian LASSO for QTL mapping and unobserved phenotype prediction. Our method, the extended Bayesian LASSO (EBL), introduces locus-specific regularization parameters and utilizes a parameterization that clearly separates the overall model sparsity from the degree of shrinkage of individual regression parameters. We use simulated data to investigate the performance of the EBL relative to the Bayesian LASSO in mapping QTL and in predicting unobserved phenotypes. We also compare the performance of the EBL to the Bayesian adaptive LASSO (BAL) recently proposed by Sun et al. (2010), which also assumes locus-specific regularization parameters.     

Mutation of an upstream cleavage site in the BMP4 prodomain leads to tissue-specific loss of activity

ProBMP4 is initially cleaved at a site adjacent to the mature ligand (the S1 site) allowing for subsequent cleavage at an upstream (S2) site. Mature BMP4 synthesized from a precursor in which the S2 site cannot be cleaved remains in a complex with the prodomain that is targeted for lysosomal degradation, and is thus less active when overexpressed in Xenopus. Here we report that mice carrying a point mutation that prevents S2 processing show severe loss of BMP4 activity in some tissues, such as testes and germ cells, whereas other tissues that are sensitive to Bmp4 dosage, such as the limb, dorsal vertebrae and kidney, develop normally. In a haploinsufficient background, inability to cleave the S2 site leads to embryonic and postnatal lethality due to defects in multiple organ systems including the allantois, placental vasculature, ventral body wall, eye and heart. These data demonstrate that cleavage of the S2 site is essential for normal development and, more importantly, suggest that this site might be selectively cleaved in a tissue-specific fashion. In addition, these studies provide the first genetic evidence that BMP4 is required for dorsal vertebral fusion and closure of the ventral body wall.     

Carrier-mediated delivery of peptidic drugs for cancer therapy

Protein and peptide drugs are used for treatment of a variety of ailments. However, their wider use has been hindered by issues such as poor bioavailability in vivo and the cost involved in producing these drugs. This review discusses the various carrier-mediated methods used for delivery of peptide and protein drugs, with emphasis on liposomal and microspherical drug delivery systems. A brief look at the types of peptidic drugs currently in use clinically, and a brief discourse on several novel ideas for better protein delivery systems for cancer therapy is included.     

Targeted therapy for cancer using pH-responsive nanocarrier systems

Most of the conventional chemotherapeutic agents used against cancer have poor efficacy. An approach to improve the efficacy of cancer chemotherapy is the development of carrier systems that can be triggered to release the anticancer drug in response to extracellular or intracellular chemical stimuli. To this end, pH-responsive nanocarriers have been developed to target drugs either to the slightly acidic extracellular fluids of tumor tissue or, after endocytosis, to the endosomes or lysosomes within cancer cells. These systems can release the drug by specific processes after accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect or they can release the drugs in endosomes or lysosomes by pH-controlled hydrolysis after they are taken up by the cell via the endocytic pathway. This strategy facilitates the specific delivery of the drug while reducing systemic side-effects with high potential for improving the efficacy of cancer chemotherapy.     

Netrin-1 in the developing enteric nervous system and colorectal cancer

Netrin-1 is a well-characterised chemoattractant involved in neuronal guidance in the developing enteric nervous system (ENS), but it is also a regulator of tumorigenesis. Two of its well-characterised receptors, deleted in colorectal cancer (DCC) and uncoordinated-5 homolog (UNC-5H), belong to a family of dependence receptors that transmit either pro- or anti-apoptosis signals depending on the availability of ligand, in this case netrin-1. This review summarises these two effects of netrin-1 and highlights the additional research needed information about to allow better utilisation of netrin-1 as a therapeutic target for axonal regeneration in the context of colorectal cancer.     

The biosynthesis of metallothionein in rat liver and kidney after administration of cadmium

The biosynthesis of the cadmium-binding protein, metallothionein, was studied in rat liver and kidney after injection of cadmium chloride. A simplified procedure for the isolation of metallothionein from liver and kidney tissues was devised. It was found that the concentration of a subcutaneously injected dose of 30 μmoles of ¹⁰⁹CdCl₂/kg in the liver reached the maximum within 36 h. Thereafter, a slow decrease in the concentration of the isotope was noted during the 3 week period. In the kidney, the isotope was taken up in two phases. During the first phase the uptake was faster and lasted for about 4 days. The second phase of ¹⁰⁹Cd accumulation showed a slower increase in the concentration of the isotope. In both liver and kidney tissues 75–80% of the ¹⁰⁹Cd was associated with metallothionein. Amino acid incorporation studies revealed that active biosynthesis of metallothionein took place in the kidney as well as in the liver of cadmium-exposed rats. The turnover of ³⁵S-labeled metallothionein was also investigated and the half-lives of the hepatic and the renal metallothionein were found to be 2.8 and 5 days, respectively.